What is the treatment for myositis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Introduction to Myositis Treatment

Myositis, a group of inflammatory muscle diseases, requires a comprehensive treatment approach. The primary goal of treatment is to reduce inflammation, improve muscle strength, and prevent long-term damage.

First-Line Treatment

The standard initial treatment for myositis is high-dosed glucocorticoids, such as prednisone 1. However, this treatment may result in relatively slow improvement of muscle strength.

Alternative and Adjunctive Therapies

Intravenous Immunoglobulin (IVIg)

IVIg has shown promise as an add-on therapy to standard glucocorticoid treatment, particularly in patients with refractory myositis or those who are treatment-naive 1, 2. The dosing of IVIg is typically 2 g/kg body weight, administered monthly 3.

Immunomodulatory Therapies

Immunosuppressants, such as azathioprine, mycophenolate, methotrexate, or cyclosporine, may be used as steroid-sparing agents or in patients who are insufficiently responsive to corticosteroids 2.

Biologic Agents

Rituximab and tacrolimus may offer additional benefit in patients with myositis, although their use is not yet widely established 2.

Special Considerations

Myositis-Associated Interstitial Lung Disease (ILD)

Patients with myositis-ILD require a multidisciplinary approach to management, involving both rheumatology and pulmonary specialists 4.

Secondary Causes of Myositis

Infections, drugs, rheumatologic diseases, and malignancies can cause myositis, and identifying these underlying causes is crucial for effective treatment 5.

Treatment Caveats

  • The treatment approach may vary depending on the specific type of myositis, such as polymyositis, dermatomyositis, or inclusion body myositis.
  • Patients with sporadic inclusion body myositis (s-IBM) may have a limited response to treatment, and high-dose IVIg may be mildly effective in preventing disease progression or inducing mild improvement 3.
  • Long-term studies are needed to evaluate the benefit of IVIg therapy in s-IBM.

Conclusion

The treatment of myositis requires a comprehensive and individualized approach, taking into account the specific type of myositis, underlying causes, and disease severity. A combination of glucocorticoids, IVIg, and immunomodulatory therapies may be necessary to achieve optimal outcomes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.